NBD AI Bulletin - Joincare Pharmaceutical Group Industry Co Ltd (the Company) issued a performance forecast, expecting the Company's net profit attributable to shareholders of the listed company in 2020 to be 1.073 billion yuan~1.163 billion yuan, an increase of 179 million yuan~268 million yuan or by 20%~30% from a year ago.
The performance is strongly driven by the rapid increase in sales of chemical agent Ilaprazole Sodium for Injection after the inclusion in medical insurance, traditional Chinese medicine preparations antiviral particles, and API meropenem for injection/meropenem with sodium carbonate as well as antibody reagent test kit for coronavirus. Plus, the growth of government subsidies received and proceeds from the wholly-owned subsidiary Livzon Pharmaceutical Group Inc.'s sale of its stake in Minitech Medical (Jiangsu) Ltd. also pushed up the business performance.
Joincare Pharmaceutical Group Industry Co., Ltd.'s chairman is Zhu Baoguo, male, 59, with a bachelor's degree. Joincare Pharmaceutical Group Industry Co., Ltd.'s president is Yu Xiong, male, 60 years old, researcher, bachelor of science at Fudan University.
Tips on "Stock Trends":
1. The number of shares held by northbound investors in the Company increased by 2.0487 million in the past 30 days, representing 0.11% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.